ACE2 and COVID-19: A previous study summarized the rationale for using SGLT2i for patients with DM who develop COVID-19; it reduces serum lactate levels, inhibits Na+/H+ exchanger activity, activates the alternative renin–angiotensin–aldosterone system pathway by activating ACE2 and reduces proinflammatory cytokine levels [80].